Translational Medicine
Open Access

Department of Internal Medicine, Rush University Medical Center, Chicago, United States

Publications

• Research Article   
  Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Elicits Anti-Tumor Response in Melanoma and Triple Negative Breast Cancer Murine Model
  Author(s): Eileena F Giurini, Michael Williams, Adam Morin, Andrew Zloza* and Kajal H Gupta*
  
  Following the breakthrough of Immune Checkpoint Inhibitors (ICIs), a new era of immuno-oncology agents has emerged and established immunotherapy as a part of cancer treatment. Despite the improving outcomes and durability of response to ICIs, unfortunately many patients with initial response are known to develop acquired resistance later. There is increasing interest in potentially using anti-pathogen immune response to induce an antitumor immune response, which has led to rethinking into how the efficacy of anti-pathogen could be further enhanced. The immunostimulatory effects of anti-pathogen treated tumors in combinations with ICI are known to potentially amplify anti-tumor immunity resulting in increased tumor responses and improved outcomes. Antipathogen treated tumors are immune-infiltrated “hot” tumors demonstrate higher treatment response rates.. View More»
  DOI: 10.35248/2161-1025.22.12.268

  Abstract HTML PDF